Stigma in drug research holding back new therapies
October 10, 2022 DOI: 10.54377/4346-4c8c (opens in new tab) via OpenAlex
Summary
AI-generated from the abstractSeveral drugs previously known as illicit party substances—ketamine, medicinal cannabis, MDMA, psilocybin, and DMT—are being investigated as therapies for mental illness. The text argues that these treatments should continue to undergo proper clinical trials rather than being adopted prematurely. Mental health disorders are a growing cause of disability, and these novel therapies offer potential new options, but rigorous evaluation remains essential.
Study at a glance
| Characteristics | Theoretical or philosophical paper |
|---|---|
| Topics | Cannabis MDMA Psilocybin |
| Keywords | Hallucinogen Psychiatry |
| Key finding | Argues that while party drugs like ketamine and psychedelics are being considered for mental health therapies, proper clinical trials should not be abandoned. |
Abstract
Therapy is turning to drugs previously known for being illicit party substances. But there’s no reason to abandon proper trials. A range of new therapies for mental illness were previously considered unthinkable — party drugs including ketamine, medicinal cannabis and psychedelics like MDMA, psilocybin and DMT. With mental health disorders a growing cause of disability […]